Anatomy, course and clinical pattern guide targeted investigation; infection must be considered before immunosuppression.
Terminology and draft status
Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.
01Examine, document and collaborate
Uveitis is a group of diseases that becomes more manageable with knowledge, systematic examination and follow-up. Ophthalmologists directly observe intraocular inflammation; collaboration with rheumatology, immunology, infectious diseases and other disciplines remains essential when systemic disease or treatment requires it. Direct visual access does not establish superiority over other specialties. 1
Obtain age, sex, onset, duration, laterality, recurrence, systemic symptoms and diseases, medicines and family history, using a questionnaire when helpful. Combine complete ophthalmic examination with systemic assessment. Record baseline findings, especially keratic precipitates, before treatment changes their appearance, without delaying sight-saving care. Continue learning, request tests for a reasoned differential, and tailor treatment and surveillance. 1 3 6
Anterior disease often causes redness, photophobia, pain and reduced vision. The export mnemonic RSPV refers to those warning symptoms rather than a validated diagnostic test. Intermediate or posterior disease may present with floaters, photopsia and gradual blur, sometimes with little pain or redness. A quiet-looking eye does not exclude serious inflammation. 1
02Classify site, cause and course
Distinguish infectious causes (viral, bacterial, fungal or parasitic), noninfectious immune-mediated disease with or without systemic association, masquerades including neoplasia, and undifferentiated or idiopathic cases. These are diagnostic categories, not an assumption that all inflammation should receive steroids alone. 1
Use the predominant inflammatory site: anterior chamber, vitreous, or retina/choroid for anterior, intermediate or posterior uveitis. Panuveitis involves anterior chamber, vitreous and retina/choroid without a predominant site. Complications such as macular oedema do not themselves change the anatomical class; distinguish vitreous spill-over from primary intermediate inflammation. 1 2
Describe onset as sudden or insidious; duration as limited (≤3 months) or persistent (>3 months). Acute means sudden onset with limited duration. Recurrent episodes are separated by inactive, untreated intervals ≥3 months, correcting the export’s >3-month boundary. Chronic disease persists and relapses in <3 months after treatment stops. The descriptors support consistent communication rather than replacing aetiological diagnosis. 1 2
03Read the slit-lamp and fundus pattern
Assess anterior chamber cells before dilation in a darkened room with high magnification (the export specifies ≥16×), a bright 1×1 mm slit and the pupil as dark background. Record flare, fibrin, hypopyon, synechiae, iris changes, pressure and posterior findings as well as cells. The table retains signs from every anatomical region. 1
Large greasy mutton-fat precipitates suggest a granulomatous pattern, for example sarcoidosis or tuberculosis; small fine deposits are often called nongranulomatous. Diffuse stellate deposits support Fuchs uveitis in the right context, but are not alone pathognomonic. SUN research classification combines several findings and exclusions and does not replace clinical diagnostic judgement. 1 4
A hypopyon in a red painful eye and a relatively quiet eye have different differential diagnoses. Behçet disease may produce a mobile shifting hypopyon with little fibrin, but redness and mobility are not sufficient to diagnose Behçet or exclude infection. Use the pattern table as a set of clues, including herpetic disease, JIA, sarcoidosis, tuberculosis, syphilis and spondyloarthritis. 1
| Site | Signs |
|---|---|
| Anterior | Chamber cells, flare, fibrin or hypopyon; anterior/posterior synechiae, iris nodules or atrophy, keratic precipitates and band keratopathy. |
| Intermediate | Vitreous cells beyond anterior spill-over, snowballs and pars-plana snowbanks; peripheral vascular sheathing may accompany disease, not isolated proof of pars-plana vasculitis. |
| Posterior | Vascular sheathing/vasculitis, retinal or choroidal lesions; macular or disc oedema, optic neuritis, tractional/rhegmatogenous/exudative detachment and neovascularisation may occur. |
| Pattern | Possible causes and limits |
|---|---|
| Unilateral inflammation | Consider infection such as herpes or toxoplasmosis, but noninfectious disease is also possible. |
| Iris atrophy and high pressure | Suggests viral/herpetic anterior uveitis; not diagnostic alone. |
| Band keratopathy | Can accompany JIA or sarcoidosis and other chronic disease. |
| Marked posterior synechiae | May occur in JIA, sarcoidosis or spondyloarthritis; assess the whole phenotype. |
| Koeppe or Busacca iris nodules | Consider sarcoidosis, tuberculosis and syphilis; no single specific aetiology. |
| Quiet white eye in a child | JIA-associated uveitis can be asymptomatic; screening follows risk and guideline, not symptoms alone. |
04Order tests that answer a clinical question
Targeted laboratory testing and imaging identify infection that changes therapy or a systemic condition affecting health. Some screening, particularly syphilis serology in otherwise unexplained disease, remains appropriate; avoiding indiscriminate panels does not mean withholding useful tests. The export’s ST reminder covers sarcoidosis, syphilis and tuberculosis, but is not a mandatory identical panel for every presentation. 1 3 7
Select chest imaging and markers such as ACE or lysozyme for suspected sarcoidosis; neither a raised nor a normal marker alone establishes or excludes it. Evaluate tuberculosis with IGRA/QuantiFERON or PPD and chest assessment according to exposure and phenotype; positive immune tests do not prove active ocular infection. For syphilis, interpret a treponemal test such as FTA-ABS with a nontreponemal test and clinical context rather than FTA-ABS alone. 1
Aqueous or vitreous PCR and selected biopsy can resolve suspected viral infection, masquerade or other uncertain disease when results will change care. Tissue sampling has risks and is not routine for everyone. Serum herpes antibodies are commonly positive and generally do not identify ocular infection; a negative serum test is not a universal exclusion, particularly early or in immunocompromise. 1 7
05Separate control from remission
Aim for inactive inflammation while preserving vision and limiting treatment toxicity. Infections require organism-directed treatment, sometimes with carefully timed anti-inflammatory therapy. Immune-mediated disease may require local or systemic corticosteroids and steroid-sparing treatment under specialist supervision. Do not label inactivity maintained by therapy as drug-free remission. 1
The original two-year steroid-free target is a long-term treatment strategy, not the SUN definition of remission. SUN remission means inactive disease ≥3 months after all treatment for the eye disease has stopped. In selected chronic noninfectious disease, maintaining inactivity for 2 years after stopping systemic steroids before tapering a nonalkylating immunosuppressant can be considered; this is not a universal rule or proof of remission. 1 2 5
Follow-up checks subclinical activity, acuity, pressure, complications and treatment toxicity, including blood count and liver or renal testing appropriate to the medicine. The export suggests 6–8-week visits even when quiet; frequency must instead reflect disease, treatment and stability, with earlier review for active disease or adverse effects. The Ocular Immunology and Uveitis Foundation website uveitis.org is an original resource lead; its questionnaire and current content were not independently inspected here. 1
What are the main learning points?
Classify and document inflammation, investigate a clinical differential, separate infection from immune-mediated disease and monitor control and toxicity in the individual patient.
Which findings require urgent assessment?
Rapid visual loss, severe pain, marked inflammation, pressure rise, suspected infection or neurological disease; new flashes or field loss also require prompt examination.
References and access status
- 1Immutable original export; attributed to Dr. Al-Baraa Al-Qubaisi
Original read; recording, speaker appointment and resource questionnaire unverified.
- 2SUN Working Group: standardization workshop (2005)
Main nomenclature tables and corresponding text read; consensus, not treatment trial.
- 3Jabs and Busingye: Approach to the Diagnosis of the Uveitides (2013)
PubMed abstract read; clinical perspective, not diagnostic accuracy trial.
- 4SUN: Classification Criteria for Fuchs Uveitis Syndrome (2021)
Abstract and indexed selected criteria inspected; research classification differs from clinical diagnosis.
- 5Jabs: Immunosuppression for the Uveitides (2018)
Indexed selected tapering recommendation and PubMed abstract inspected; whole report not read.
- 6BVA/DOG: systematic history in uveitis (2025)
One-page guidance text read; not a randomized study.
- 7BVA/DOG: diagnostic approach in uveitis (2022)
One-page guidance text read; select tests by inflammatory site and phenotype.
Original lecture link
For patients
Uveitis is inflammation inside the eye; some forms cause pain and redness, others mainly floaters or blurred vision.
Examination and selected tests determine the cause. Use prescribed medicines and attend follow-up; do not start or stop steroids on your own. This is not a substitute for individual assessment.
Seek prompt help for redness, light sensitivity, pain or changing vision, and immediate care for sudden severe symptoms.
Rapid loss of vision, severe pain, marked inflammation, pressure rise, retinal symptoms or suspected infection require urgent assessment.